Walleye Capital
ACRS icon

Walleye Capital’s Aclaris Therapeutics ACRS Stock Holding History

Walleye Capital’s Portfolio ACRS Stock Details ACRS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		– Sell
-300
Closed -$3.11K – 4802
2023
Q2 		$3.11K Buy
+300
New +$2.71K ﹤0.01% 4103
2022
Q4 		– Sell
-2,200
Closed -$35K – 3125
2022
Q3 		$35K Buy
+2,200
New +$34.7K ﹤0.01% 2654

Other funds holding ACRS

RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
BCM
BML Capital Management Zionsville, Indiana $176M AUM 123.21% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.1B AUM 799.93% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
FLSM
Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $2.05B AUM 161.37% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
DC
Decheng Capital Menlo Park, California $732M AUM 275.56% 1-Year Est. Return

Walleye Capital's ACRS Position: Q2 2026 in Review

Walleye Capital opened a new position in Aclaris Therapeutics (ACRS) in Q2 2026: 19,576 shares worth $104K. The stake represents ﹤0.01% of the portfolio and ranks #3888 among its holdings. This is a return to the name: Walleye Capital previously reported a position in ACRS as recently as Q1 2025.

Walleye Capital first reported a position in ACRS in Q2 2019 and has held it in 10 quarters since. The position peaked at $6.6M in Q4 2022. 149 funds tracked by Wall St. Rank hold ACRS as of Q2 2026.

  • Walleye Capital held 19,576 shares of Aclaris Therapeutics worth $104K as of Q2 2026.
  • Aclaris Therapeutics was a new Walleye Capital position in Q2 2026.
  • Aclaris Therapeutics made up ﹤0.01% of Walleye Capital's portfolio in Q2 2026, its #3888 holding.
  • Walleye Capital first reported a position in Aclaris Therapeutics in Q2 2019 and has held it in 10 quarters since.
  • Walleye Capital's Aclaris Therapeutics position peaked at $6.6M in Q4 2022.
  • 149 funds tracked by Wall St. Rank held Aclaris Therapeutics as of Q2 2026.

Based on Walleye Capital's 13F filing for Q2 2026, filed 3 Aug 2026.